drugset / Trial / NCT02778204
Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection
Phase 1
Completed
47 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · collabGlaxoSmithKline · collabViiV Healthcare · collab
Non-randomizedParallel-groupOpen-labelPrevention
Summary
This study aimed to evaluate the safety, tolerability, and pharmacokinetics of maraviroc in infants at risk for mother-to-child HIV transmission, and to determine an appropriate dose of maraviroc during the first six weeks of life.
Timeline
- Start
- 2017-06-05
- Primary completion
- 2019-09-06
- Completion
- 2019-11-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Maraviroc | Other / unclassified | 8 mg/kg | Oral |